Eli Lilly Signs Five-Years License Agreement with Evox Therapeutics for its DeliverEX Platform

 Eli Lilly Signs Five-Years License Agreement with Evox Therapeutics for its DeliverEX Platform

Eli Lilly Signs Five-Year License Agreement with Evox Therapeutics for its DeliverEX Platform

Shots:

  • Evox to receive $20M upfront, research funding over three years, $10M investment in exchange for a convertible bond, pre-clinical & clinical development, regulatory & commercial milestones for up to $1.2B plus royalties on sales. Evox will take care of material supply for in vivo studies and exosome engineering for brain/CNS-targeting, drug loading and analytics and some in vitro assay development
  • Eli Lilly to get rights for Evox’s DeliverEX platform to develop RNAi & ASO drug payloads for neurological disorders and will get hold of any developed candidates and technology transfer post completion of pre-clinical proof of concept studies
  • DeliverEX platform allows loading of exosomes with diverse drug cargos utilizing tissue targeting capabilities of exosomes further providing manufacturing plus purification for advanced exosome therapeutics

Click here to read full press release/ article | Ref: PRNewswire | Image: Pharmaworld

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post